Potential target for an immunotherapeutic approach to stop...

Details Potential target for an immunotherapeutic approach to stop... Potential target for an immunotherapeutic approach to stop...

C - Chemistry, Metallurgy

12

N

C12N 15/12 (2006.01) A61K 31/70 (2006.01) A61K 38/17 (2006.01) A61K 39/395 (2006.01) C07H 21/00 (2006.01) C07K 14/47 (2006.01) C07K 14/81 (2006.01) C12P 21/08 (2006.01) C12Q 1/68 (2006.01) G01N 33/566 (2006.01) G01N 33/577 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2086576

ABSTRACT A cDNA reconstructed from the antisense strand of human APP gene encodes a 224 amino acid (aa) protein "Cadrac", which contains a 25 aa domain that is capable of interacting with the human dopamine receptor and the human brain Ca2+ channel protein. Both dopamine and Ca2+ signalling are likely to be involved in Parkinson's disease. The human APP gene is involved in Alzheimer's disease and there is an established relationship between Alzheimer's disease and Parkinson's disease. Since `Cadrac' cannot be expressed in healthy humans the protein is potentially a good candidate for an immunotherapeutic approach to stop Parkinson's disease in humans.

Affiliated with

Also associated with

Rating

Potential target for an immunotherapeutic approach to stop... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Potential target for an immunotherapeutic approach to stop..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Potential target for an immunotherapeutic approach to stop... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1384234